Investigational drug · Phase 3
Larazotide Acetate
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Celiac Disease, Celiac Disease in Adolescents.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
30
Any phase or sponsor naming "Larazotide Acetate"
First trial start
2027
Feb 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Larazotide Acetate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Celiac Disease
- Celiac Disease in Adolescents
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Larazotide Acetate" as an intervention, largest first.
- Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac DiseasePivotal-lookingNot yet recruiting
Interlude Biopharma Co.Industry
NCT07944625 · 414 participants (planned) · Start Feb 2027 · Primary completion Aug 2028
Drug: Larazotide Acetate; Placebo · For: Celiac Disease; Celiac Disease in Adolescents
- A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac DiseasePivotal-lookingCompleted
9 Meters Biopharma, Inc.Industry
NCT01396213 · 342 participants · Start Nov 7, 2011 · Primary completion Aug 20, 2013
Drug: Larazotide Acetate; placebo · For: Celiac Disease
Sites: Birmingham, Alabama; Mesa, Arizona; Tucson, Arizona · 62 sites in all
- Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD SymptomsPivotal-lookingTerminated
9 Meters Biopharma, Inc.Industry
NCT03569007 · 307 participants · Start May 29, 2019 · Primary completion Jul 21, 2022
Drug: Larazotide; Matching Placebo · For: Celiac Disease
Sites: Saraland, Alabama; Scottsdale, Arizona; Tucson, Arizona · 160 sites in all
- Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac DiseasePivotal-lookingCompleted
9 Meters Biopharma, Inc.Industry
NCT00492960 · 171 participants · Start Aug 2007 · Primary completion Oct 2008
Drug: larazotide acetate; placebo · For: Celiac Disease
Sites: Scottsdale, Arizona; Colorado Springs, Colorado; Chicago, Illinois · 23 sites in all
- AT1001 for the Treatment of Long COVIDPivotal-lookingCompleted
Massachusetts General HospitalAcademic, hospital or other
NCT05747534 · 107 participants · Start May 31, 2023 · Primary completion Jun 18, 2026
Drug: Larazotide Acetate; Placebo · For: Long COVID; Long COVID-19; Post Acute COVID-19 Syndrome and 1 more
Sites: Boston, Massachusetts
- Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac DiseasePivotal-lookingCompleted
9 Meters Biopharma, Inc.Industry
NCT00620451 · 105 participants · Start Feb 2008 · Primary completion Jul 2009
Drug: larazotide acetate; placebo · For: Celiac Disease
Sites: Orange, California; San Francisco, California; Torrington, Connecticut · 33 sites in all
- Open-Label Phase 3 Long-Term Safety Study of MigalastatPivotal-lookingTerminated
Amicus TherapeuticsIndustry
NCT01458119 · 85 participants · Start Oct 14, 2011 · Primary completion Feb 17, 2016
Drug: migalastat hydrochloride · For: Fabry Disease
Sites: Atlanta, Georgia; Chicago, Illinois; Kansas City, Kansas · 25 sites in all
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT02194985 · 84 participants · Start Mar 14, 2015 · Primary completion Oct 23, 2019
Drug: migalastat HCl 150 mg · For: Fabry Disease
Sites: Atlanta, Georgia; Kansas City, Kansas; Grand Rapids, Michigan · 28 sites in all
9 Meters Biopharma, Inc.Industry
NCT00362856 · 80 participants · Start Sep 13, 2006 · Primary completion Mar 6, 2007
Drug: larazotide acetate; Placebo · For: Celiac Disease
Sites: Scottsdale, Arizona; San Diego, California; Boston, Massachusetts · 9 sites in all
- Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT01218659 · 68 participants · Start Sep 8, 2011 · Primary completion May 27, 2014
Drug: migalastat hydrochloride; agalsidase · For: Fabry Disease
Sites: Los Angeles, California; Aurora, Colorado; Decatur, Georgia · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stress Conditions in a Mouse Model of Eosinophilic Enteritis.
Yamamoto K, Tanaka F, Nishida Y, et al. · Digestion 2026
- Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration.
Damianos JA, Bledsoe A, Camilleri M, et al. · Gut 2026
- Integrated Role of Microbial, Fungal, and Plant-Derived Interventions in the Management of Celiac Disease: A Narrative Review.
Kubala K, Pietrucha T, Goldyn M, et al. · Cureus 2026
- Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model.
Huang YC, Chiang Chiau JS, Cheng ML, et al. · Pediatr Neonatol 2026
- Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment.
Yu F, Chen Y, Ouyang S, et al. · J Control Release 2025
- Larazotide Acetate Protects the Intestinal Mucosal Barrier from Anoxia/Reoxygenation Injury via Various Cellular Mechanisms.
Kim J, Madan JP, Laumas S, et al. · Biomedicines 2025
Also in development for Celiac Disease
- AmlitelimabSAR445229Phase 39 trials
Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease
- TEV-53408Phase 32 trials
Teva · Vitiligo, Celiac Disease
- DONQ52Phase 21 trial
Chugai Pharmaceutical · Celiac Disease
- FB102Phase 21 trial
Forte Biosciences, Inc. · Celiac Disease
- KAN-101Phase 21 trial
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA · Celiac Disease, Coeliac Disease
- TAK-101Phase 21 trial
Takeda · Celiac Disease
- ZED1227Phase 21 trial
Dr. Falk Pharma GmbH · Celiac Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.